About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
Sustainable development/ESG“We help people live healthy lives in a healthy world”. This is our mission, which reflects Polpharma’s priorities. We provide patients with high-quality, effective, safe and accessible products while operating responsibly in the society, the environment and with respect to key stakeholders.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
The new location will enable Polpharma to work more closely with key API suppliers, improve process predictability, and support the advancement of high quality and ESG standards across the region.“India is a global center of excellence for APIs – it’s the fact we cannot ignore, despite advocating for building Europe’s independence when it comes to pharmaceutical ingredients. Being present on the ground allows us to collaborate more closely with partners, make faster decisions, and responsibly strengthen our supply chain. This is an important milestone for the Polpharma Group and proof that we continue to build long‑term value for patients, partners, and the entire healthcare ecosystem,” says Sebastian Szymanek, CEO of Polpharma Group.Key benefits of opening the India office:Supply chain stability and continuity – earlier risk identification and greater resilience to disruptions.Stronger operational and quality collaboration – direct oversight of supplier processes, including GMP compliance.Access to technological know‑how –India is a leader in API process optimization and finished product developments, which enables us to accelerate our developments, support technology transfer, expand our portfolio to better address patients needs and strengthen our competitiveness, e.g. by building various types of collaborations and partnerships, also with innovative R&D platforms enabling co-development of ambitious projects.Enhanced ESG management – capability to conduct on‑site audits (EcoVadis, PSCI), corrective actions and supplier development programs.Building ESG maturity among partners – supporting smaller suppliers in meeting increasing regulatory and market expectations.The opening of the India office represents a significant step in strengthening Polpharma’s global collaboration and advancing its mission: helping people live healthy lives in a healthy world.
